SUPN – Invest Chronicle

Stock

SUPN’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect?

The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. This year’s metric has recorded a Price increase of 8.60%. However, over the past six months, we’ve seen a weaker performance of 14.88%. The price of SUPN fallen by 2.01% over the last 30 days. And in the last five days, it has fallen by -6.24%. The stock market performance of Supernus Pharmaceuticals Inc has been fairly unsteady. Over the last year, the company’s stock hit its highest at $39.09 on 04/21/23, while the

Stock Investing

Be ready for liftoff for Supernus Pharmaceuticals Inc. (SUPN)

Qelbree, a drug developed by Supernus Pharmaceuticals, Inc. (SUPN), recently received FDA approval. Consequently, SUPN shares traded at 30.11 USD on April 5th for a gain of 12.7%. Qelbree is specifically approved to treat attention deficit hyperactivity disorder in patients between the ages of 6 and 17 years. Despite its high prevalence, this diagnosis holds excellent commercial potential. The ADHD symptoms include hyperactivity, difficulty concentrating, impulsivity, and difficulties managing daily tasks. Children with ADHD account for more than 6 million people in the United States solely. Supernus has made remarkable efforts to secure approval. They have conducted four phases III

Tag: SUPN

SUPN’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect?

Be ready for liftoff for Supernus Pharmaceuticals Inc. (SUPN)

Quick Links

Categories